

PRESS RELEASE

Successful placing of shares on the market – Great interest shown by investors, transaction oversubscribed | Higher free float and wider shareholder base

Dietlikon, 3 September 2013 – The blocks of shares held by Implenia's two major shareholders Rudolf Maag and Ammann Group, who last week announced that they were planning to reduce their stake, have been successfully placed on the market. Implenia is pleased that both shareholders will continue to hold shares in the company.

Investors were very keen to purchase the shares on offer, which together represent around 9% of Implenia's share capital, and the transaction was oversubscribed. The successful placing of these shares will allow Implenia to increase its free float and thus to further widen its shareholder base. Implenia extends a warm welcome to its new shareholders and would like to thank them for the trust they have placed in the company.

Contact at Implenia: Beat Fellmann CFO +41 44 805 45 00 beat.fellmann@implenia.com

Implenia is Switzerland's leading construction and construction services company. Formed in 2006 from the merger between Zschokke and Batigroup, Implenia can look back on approximately 150 years of history in the construction industry. The company brings the expertise of its highly skilled Modernisation & Development, Buildings and Tunnelling & Civil Engineering Sectors, and its Switzerland and Norway Regions under the single roof of a nationally and internationally active company. With its integrated business model and specialists operating in all its divisions, Implenia can manage a building project through its entire lifecycle and deliver work that is economical, integrated and customer-centric. The focus is on striking a sustainable balance between financial success and social and environmental responsibility.

Implenia has its head office in Dietlikon near Zurich, employs more than 6700 people and generated a revenue of around CHF 2.7 billion in 2012. The Company is listed on the SIX Swiss Exchange (IMPN, CH0023868554). Further information at www.implenia.com.